Inclusion Criteria:  1. Subject age is greater than or equal to 18 years of age. 2. Subject can speak and read English. 3. Subject weight is greater than 40 kg. 4. Subject is scheduled for redo, triple valve, or complex aortic cardiac surgery with cardiopulmonary bypass. 5. Subject has ability to comprehend and willingness to sign Informed Consent Form (ICF). 6. If female of childbearing potential, must have a negative pregnancy test and agree to use one of the following methods of contraception during the course of study participation: abstinence, intrauterine contraception device, hormonal method, or barrier method. 7. Subject agrees to not participate in another interventional study during study participation. 8. The clinical site can obtain both possible platelet products (CSP and RSP) as needed per the study protocol given the subject's anticipated surgery date.  Exclusion Criteria:  1. Subject has history of known repeated, severe transfusion reactions. 2. Subject requires washed products, volume reduced products, or products with additive solution. 3. Subject is planned to receive autologous or directed transfusions. 4. Subject has or is expected to require post-surgical ventricular assist device (VAD), hemodialysis, or extracorporeal membrane oxygenation (ECMO) within 24 hours of the Study Treatment Window. 5. Subject is thrombocytopenic (less than 100 x 103 platelets/μL) on most recent measurement. 6. Subject is pregnant or breastfeeding. 7. Subject is a prisoner 8. Subject has active infection. 9. Subject refuses blood products. 10. Subject has a history of unprovoked deep vein thrombosis (DVT) or unprovoked pulmonary embolism (PE). 11. Subject has previously been enrolled and received a study platelet transfusion. 12. Subject has known bleeding diathesis (hemophilia, Von Willebrand Disease, or others) 13. At discretion of subject's physician, Sub-Investigator (SI), or Principle Investigator (PI).